AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17202945 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone-valacyclovir
Number of subjects: 150
Study 17202945 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (prednisolone and prednisolone-valacyclovir)
Number of subjects: 150
Study 17202945 — intervention group
Group type: EXPERIMENTAL
Intervention: Age groups and paralysis status
Number of subjects: 150
Study 14704645 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio-Hep-B vaccine (2.5 microg)
Number of subjects: 28
Study 14704645 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio-Hep-B vaccine (5 microg)
Number of subjects: 28
Study 11684212 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily rhDNase (2.5 mg)
Number of subjects: 48
Study 11684212 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate-day rhDNase (2.5 mg)
Number of subjects: 48
Study 11684212 — intervention group
Group type: COMPARATOR
Intervention: Hypertonic saline (5 mL 7%)
Number of subjects: 48
Study 11684212 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily rhDNase vs Hypertonic saline
Number of subjects: 48
Study 11684212 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily rhDNase vs Alternate-day rhDNase
Number of subjects: 48
Study 11684212 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost comparison
Number of subjects: 48
Study 9596315 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized recombinant human DNase I (rhDNase)
Number of subjects: 349
Study 9596315 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 349
Study 7833220 — intervention group
Group type: EXPERIMENTAL
Intervention: Icatibant 20 micrograms kg‐1
Number of subjects: 8
Study 7833220 — intervention group
Group type: EXPERIMENTAL
Intervention: Icatibant 50 micrograms kg‐1
Number of subjects: 8
Study 7833220 — intervention group
Group type: EXPERIMENTAL
Intervention: Icatibant 100 micrograms kg‐1
Number of subjects: 8
Study 7833220 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 3279488 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinolones (ciprofloxacin, enoxacin)
Number of subjects: 0
Study 3279488 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinolones (ciprofloxacin)
Number of subjects: 0
Study 31815661 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D and omega-3 fatty acids co-supplementation
Number of subjects: 0
Study 31815661 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27613885 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-nicotine content (RNC) cigarettes
Number of subjects: 717
Study 27613885 — intervention group
Group type: COMPARATOR
Intervention: Normal-nicotine content (NNC) cigarettes
Number of subjects: 717
Study 25886825 — intervention group
Group type: EXPERIMENTAL
Intervention: Hinged soft knee orthosis
Number of subjects: 31
Study 24053480 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg/day + Rosuvastatin 2.5 mg/day (combination group)
Number of subjects: 79
Study 24053480 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin 5 mg/day (dose escalation group)
Number of subjects: 79
Study 21631570 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide (1 mg, three times daily) for 8 weeks
Number of subjects: 170
Study 19124121 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 4444
Study 19124121 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4444
Study 17942387 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet questionnaire
Number of subjects: 533
Study 17942387 — intervention group
Group type: COMPARATOR
Intervention: Paper-and-pencil questionnaire
Number of subjects: 533
Study 15482352 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan 2.5 mg
Number of subjects: 280
Study 12661619 — intervention group
Group type: EXPERIMENTAL
Intervention: Videoconferencing for discharge planning
Number of subjects: 204
Study 12661619 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face meetings for discharge planning
Number of subjects: 204
Study 10195339 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with neurological symptoms
Number of subjects: 13
Study 10195339 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without neurological symptoms
Number of subjects: 13
Study 10195339 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 13
Study 10195339 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer duration of disease
Number of subjects: 13
Study 10195339 — intervention group
Group type: EXPERIMENTAL
Intervention: More severe cognitive deficits
Number of subjects: 13
Study 10195339 — intervention group
Group type: EXPERIMENTAL
Intervention: More pronounced psychiatric symptoms
Number of subjects: 13
Study 10195339 — intervention group
Group type: EXPERIMENTAL
Intervention: More pronounced motor disabilities
Number of subjects: 13
Study 10195339 — intervention group
Group type: EXPERIMENTAL
Intervention: More pronounced psychiatric symptoms and cognitive deficits
Number of subjects: 13
Study 8645847 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B bladder irrigation (AmBBI) at 50 mg/L over 24 hours or 50 mg/L for 7 days
Number of subjects: 53
Study 8645847 — intervention group
Group type: COMPARATOR
Intervention: Oral fluconazole at 200 mg/d for 7 days
Number of subjects: 53
Study 2140996 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafarelin 400 micrograms daily
Number of subjects: 82
Study 2140996 — intervention group
Group type: COMPARATOR
Intervention: Danazol 600 mg daily
Number of subjects: 82
Study 493514 — intervention group
Group type: EXPERIMENTAL
Intervention: Simethicone
Number of subjects: 169
Study 493514 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 169
Study 31600790 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative treatment for PDA
Number of subjects: 83
Study 31600790 — intervention group
Group type: COMPARATOR
Intervention: Control cohort (standard treatment)
Number of subjects: 83
Study 31600790 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative cohort
Number of subjects: 83
Study 31600790 — intervention group
Group type: COMPARATOR
Intervention: Control cohort
Number of subjects: 83
Study 31600790 — intervention group
Group type: EXPERIMENTAL
Intervention: PDA >28 days
Number of subjects: 83
Study 30408001 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexavalent vaccine (DTaP‐IPV‐HB‐PRP‐T) at 2 and 6 months, Pentavalent vaccine (DTaP‐IPV//PRP‐T) at 4 months
Number of subjects: 265
Study 30408001 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster vaccination (DTaP‐IPV//PRP‐T and pneumococcal vaccine) at 18 months
Number of subjects: 265
Study 28116506 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural block (Epi) using ropivacaine
Number of subjects: 72
Study 28116506 — intervention group
Group type: COMPARATOR
Intervention: Paravertebral block via the surgical field (PVB-sf) using ropivacaine
Number of subjects: 72
Study 26002986 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic surgery (group C)
Number of subjects: 526
Study 26002986 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery (group B)
Number of subjects: 526
Study 26002986 — intervention group
Group type: COMPARATOR
Intervention: Abdominal surgery (group A)
Number of subjects: 526
Study 26002986 — intervention group
Group type: COMPARATOR
Intervention: All groups (A, B, C)
Number of subjects: 526
Study 24165255 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous vancomycin infusion (CVI)
Number of subjects: 73
Study 24165255 — intervention group
Group type: COMPARATOR
Intervention: Intermittent vancomycin infusion (IVI)
Number of subjects: 73
Study 21386830 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronate (4 mg intravenous), n=20
Number of subjects: 40
Study 21386830 — intervention group
Group type: COMPARATOR
Intervention: Placebo, n=20
Number of subjects: 40
Study 21386830 — intervention group
Group type: COMPARATOR
Intervention: Comparison of ZOL vs. Placebo
Number of subjects: 40
Study 21386830 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronate (4 mg intravenous)
Number of subjects: 40
Study 19564877 — intervention group
Group type: EXPERIMENTAL
Intervention: diethylpropion 50 mg BID
Number of subjects: 69
Study 19564877 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 69
Study 19564877 — intervention group
Group type: EXPERIMENTAL
Intervention: diethylpropion (after switching from placebo)
Number of subjects: 69
Study 19564877 — intervention group
Group type: EXPERIMENTAL
Intervention: diethylpropion
Number of subjects: 69
Study 19564877 — intervention group
Group type: COMPARATOR
Intervention: diethylpropion and placebo
Number of subjects: 69
Study 17178091 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency-doubling perimetry (FDP)
Number of subjects: 92
Study 17178091 — intervention group
Group type: COMPARATOR
Intervention: Standard automated perimetry (SAP)
Number of subjects: 92
Study 14745664 — intervention group
Group type: EXPERIMENTAL
Intervention: Apple-pectin powder (15-16% pectin)
Number of subjects: 64
Study 14745664 — intervention group
Group type: COMPARATOR
Intervention: Placebo powder
Number of subjects: 64
Study 11736720 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymosin
Number of subjects: 353
Study 11736720 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 353
Study 9332683 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy (XRT group)
Number of subjects: 381
Study 9332683 — intervention group
Group type: COMPARATOR
Intervention: No postoperative radiotherapy (non-XRT group)
Number of subjects: 381
Study 8466064 — intervention group
Group type: COMPARATOR
Intervention: Balanced anesthesia (nitrous oxide in 40% oxygen supplemented with fentanyl, thiopental, and droperidol)
Number of subjects: 30
Study 8466064 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane-nitrous oxide (1.25 MAC)
Number of subjects: 30
Study 8466064 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane-nitrous oxide (1.25 MAC)
Number of subjects: 30
Study 3956211 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexiletine
Number of subjects: 0
Study 3956211 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31468503 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulipristal acetate (UPA)
Number of subjects: 55
Study 31468503 — intervention group
Group type: COMPARATOR
Intervention: Gonadotropin-releasing hormone agonists (GnRHa)
Number of subjects: 55
Study 30192695 — intervention group
Group type: EXPERIMENTAL
Intervention: Ubiquinol (150 mg/day)
Number of subjects: 41
Study 30192695 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 27927936 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic Blood Pressure (SBP) ≥160 mm Hg
Number of subjects: 20332
Study 27927936 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic Blood Pressure (DBP) ≥100 mm Hg
Number of subjects: 20332
Study 27927936 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing SBP and DBP categories
Number of subjects: 20332
Study 27927936 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall BP levels
Number of subjects: 20332
Study 25548848 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Number of subjects: 0
Study 25548848 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23426761 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole 400 mg QD for 28 days
Number of subjects: 36
Study 23426761 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin 600 mg QD for 28 days
Number of subjects: 36
Study 23426761 — intervention group
Group type: COMPARATOR
Intervention: Placebo QD for 28 days
Number of subjects: 36
Study 21420111 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanezumab (200 μg/kg, single intravenous dose)
Number of subjects: 64
Study 21420111 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanezumab
Number of subjects: 64
Study 21420111 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 20210207 — intervention group
Group type: EXPERIMENTAL
Intervention: Biocomplexes
Number of subjects: 0
Study 17710125 — intervention group
Group type: EXPERIMENTAL
Intervention: FFM ME-TRAP
Number of subjects: 405
Study 17710125 — intervention group
Group type: COMPARATOR
Intervention: Control (rabies vaccine)
Number of subjects: 405
Study 15531052 — intervention group
Group type: EXPERIMENTAL
Intervention: Females
Number of subjects: 24
Study 15531052 — intervention group
Group type: COMPARATOR
Intervention: Males
Number of subjects: 24
Study 11587610 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Number of subjects: 64
Study 11587610 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine plus clonidine
Number of subjects: 64
Study 11587610 — intervention group
Group type: COMPARATOR
Intervention: Isotonic sodium chloride
Number of subjects: 64
Study 9296641 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 40 mg per day for 8 weeks
Number of subjects: 40
Study 9296641 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 8295879 — intervention group
Group type: EXPERIMENTAL
Intervention: pirazinamid administered at a single dose daily or each other day
Number of subjects: 310
Study 8295879 — intervention group
Group type: EXPERIMENTAL
Intervention: multicomponent form tricox (Jemis, India) with isoniazid, rifampicin, and pirazinamid
Number of subjects: 310
Study 3726454 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of neurotensin in relevant doses
Number of subjects: 17
Study 3726454 — intervention group
Group type: COMPARATOR
Intervention: Test meal
Number of subjects: 17
Study 2568849 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of atracurium 0.125 mg kg‐1 + vecuronium 0.025 mg kg‐1
Number of subjects: 30
Study 2568849 — intervention group
Group type: COMPARATOR
Intervention: Atracurium 0.5 mg kg‐1
Number of subjects: 30
Study 2568849 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium 0.1 mg kg‐1
Number of subjects: 30
Study 31087419 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational-volitional group intervention (MoVo) consisting of four group sessions (60 min each)
Number of subjects: 800
Study 31087419 — intervention group
Group type: COMPARATOR
Intervention: Standard rehabilitation (control group)
Number of subjects: 800
Study 31087419 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational-volitional group intervention (MoVo)
Number of subjects: 800
Study 28868633 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimecrolimus 1% cream (PIM)
Number of subjects: 100
Study 28868633 — intervention group
Group type: COMPARATOR
Intervention: Low‐to‐medium‐potency topical corticosteroids (TCS)
Number of subjects: 100
Study 27108464 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural (CSE) with 0.5% heavy bupivacaine 2.5 mg
Number of subjects: 60
Study 27108464 — intervention group
Group type: COMPARATOR
Intervention: Low-dose epidural with 10ml of 0.1% bupivacaine and 2 µg/ml fentanyl
Number of subjects: 60
Study 27108464 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural (CSE)
Number of subjects: 60
Study 27108464 — intervention group
Group type: COMPARATOR
Intervention: Low-dose epidural
Number of subjects: 60
Study 23958597 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein diet (30% protein [110 g/day], 40% carbohydrates [150 g/day], 30% fat [50 g/day])
Number of subjects: 61
Study 23958597 — intervention group
Group type: COMPARATOR
Intervention: Standard protein diet (15% protein [55 g/day], 55% carbohydrates [200 g/day], 30% fat [50 g/day])
Number of subjects: 61
Study 21368076 — intervention group
Group type: EXPERIMENTAL
Intervention: Total hip arthroplasty
Number of subjects: 120
Study 21368076 — intervention group
Group type: COMPARATOR
Intervention: Bipolar hemiarthroplasty
Number of subjects: 120
Study 19702089 — intervention group
Group type: EXPERIMENTAL
Intervention: Huangban Bianxing Recipe (HBR) taken orally, one dose every day for 3 months
Number of subjects: 80
Study 19702089 — intervention group
Group type: COMPARATOR
Intervention: Ginkgo leaf tablet (19.2 mg) taken thrice a day for 3 months
Number of subjects: 80
Study 19702089 — intervention group
Group type: EXPERIMENTAL
Intervention: Huangban Bianxing Recipe (HBR)
Number of subjects: 80
Study 19702089 — intervention group
Group type: COMPARATOR
Intervention: Ginkgo leaf tablet (19.2 mg)
Number of subjects: 80
Study 16849753 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis extract (CE) - 2.5 mg THC and 1 mg cannabidiol, orally, twice daily for 6 weeks
Number of subjects: 243
Study 16849753 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta-9-tetrahydrocannabinol (THC) - 2.5 mg, orally, twice daily for 6 weeks
Number of subjects: 243
Study 16849753 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL) - orally, twice daily for 6 weeks
Number of subjects: 243
Study 15262604 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 microg/kg intrathecal morphine sulfate
Number of subjects: 100
Study 15262604 — intervention group
Group type: COMPARATOR
Intervention: Sterile normal saline placebo
Number of subjects: 100
Study 10690662 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-low-birthweight teeth
Number of subjects: 111
Study 10690662 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-birthweight teeth
Number of subjects: 111
Study 10690662 — intervention group
Group type: COMPARATOR
Intervention: Normal-birthweight controls
Number of subjects: 111
Study 10690662 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular and maxillary lateral incisors of very-low-birthweight children
Number of subjects: 111
Study 9101427 — intervention group
Group type: EXPERIMENTAL
Intervention: Low SAT Diet (25% fat, 6% saturated fatty acids)
Number of subjects: 25
Study 9101427 — intervention group
Group type: COMPARATOR
Intervention: Step-One Diet (29% fat, 9% saturated fatty acids)
Number of subjects: 25
Study 9101427 — intervention group
Group type: COMPARATOR
Intervention: Average American Diet (34% fat, 15% saturated fatty acids)
Number of subjects: 25
Study 8468114 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin once daily (single injection)
Number of subjects: 39
Study 8468114 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin twice daily (two injections at 12-hour interval)
Number of subjects: 39
Study 8468114 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin (both groups)
Number of subjects: 39
Study 3514832 — intervention group
Group type: EXPERIMENTAL
Intervention: Untreated own mother's milk
Number of subjects: 0
Study 3514832 — intervention group
Group type: COMPARATOR
Intervention: Pooled pasteurized breast milk
Number of subjects: 0
Study 31608773 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal behavioral intervention including yoga, memory compensation training, computerized cognitive training, support groups, and wellness education
Number of subjects: 272
Study 31608773 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 272
Study 31608773 — intervention group
Group type: EXPERIMENTAL
Intervention: Group support
Number of subjects: 272
Study 31608773 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher educational level, higher baseline depressive symptoms, higher baseline global cognitive functioning, and better baseline and concurrent functional abilities
Number of subjects: 272
Study 31608773 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in functional abilities
Number of subjects: 272
Study 29911495 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone Yo-Yo Intermittent Recovery Test Level 1 (Yo-Yo IR1)
Number of subjects: 17
Study 27239315 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity (active vs inactive) in males
Number of subjects: 334
Study 27239315 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist circumference in females
Number of subjects: 334
Study 27239315 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline hypertension and family history of diabetes
Number of subjects: 334
Study 24176067 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum unbound free fatty acid (FFAu) levels
Number of subjects: 1834
Study 24176067 — intervention group
Group type: EXPERIMENTAL
Intervention: FFAu levels in the fourth quartile
Number of subjects: 1834
Study 23801529 — intervention group
Group type: EXPERIMENTAL
Intervention: lisdexamfetamine (30, 50 or 70 mg/day)
Number of subjects: 336
Study 23801529 — intervention group
Group type: COMPARATOR
Intervention: OROS-MPH (18, 36 or 54 mg/day)
Number of subjects: 336
Study 23801529 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 336
Study 23801529 — intervention group
Group type: EXPERIMENTAL
Intervention: lisdexamfetamine
Number of subjects: 336
Study 20420753 — intervention group
Group type: EXPERIMENTAL
Intervention: 13C-labelled phylloquinone from kale
Number of subjects: 7
Study 17919605 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated car seat
Number of subjects: 30
Study 17919605 — intervention group
Group type: COMPARATOR
Intervention: Unheated car seat
Number of subjects: 30
Study 15945502 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beta2-agonists, beclomethasone, disodiumcromoglycate, and immunotherapy (for 14 patients in group a and 28 patients in group b)
Number of subjects: 70
Study 15945502 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beta2-agonists, beclomethasone, disodiumcromoglycate (without immunotherapy for 14 patients in group c)
Number of subjects: 70
Study 15945502 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up after five years for group (b)
Number of subjects: 70
Study 15945502 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 70
Study 12861258 — intervention group
Group type: EXPERIMENTAL
Intervention: Work methodology for enuresis
Number of subjects: 0
Study 12861258 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol based on anamnesis and urine analysis
Number of subjects: 0
Study 9835000 — intervention group
Group type: EXPERIMENTAL
Intervention: Epicardial two‐dimensional echocardiography using a 7.5 MHz cm2 transducer
Number of subjects: 23
Study 9835000 — intervention group
Group type: COMPARATOR
Intervention: Calculated CSA from the most suitable diameter assuming vessel circularity
Number of subjects: 23
Study 8983929 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha-2b (IFN)
Number of subjects: 0
Study 8983929 — intervention group
Group type: COMPARATOR
Intervention: Control group (no IFN)
Number of subjects: 0
Study 2523664 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine 1.25 mg twice daily
Number of subjects: 178